Physician profile
Catherine Bartnik
NPI 1548688773
$756.12
in general payments reported to CMS, 2019-2025
14 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2024: $247 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $155.68 | 2025 | Wegovy |
| Abbvie INC. | $124.74 | 2022 | |
| Cook Medical LLC | $96.92 | 2024 | Echotip Insight |
| Madrigal Pharmaceuticals | $81.69 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $55.89 | 2024-2025 | Dupixent |
| Braintree Laboratories, INC. | $54.88 | 2024-2025 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $49.78 | 2025 | Iqirvo |
| Janssen Biotech, INC. | $36.41 | 2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.59 | 2024 | Xifaxan |
| Organon LLC | $18.79 | 2025 | Renflexis, Hadlima |
| Olympus America INC. | $15.43 | 2024 | Single Use Electrosurgical Hemostatic Forceps |
| Takeda Pharmaceuticals U.S.A., INC. | $15.05 | 2024 | Entyvio |
| Aimmune Therapeutics, INC. | $14.77 | 2025 | Zenpep |
| Capsovision, INC. | $14.50 | 2024 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Bartnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.